express the TGFb receptor (TGFbR) and have a central role in regulating immune responses, studying the potential role of the TGFbR in DCs and how it might influence T-cell activation and modulate atherosclerosis is an area of great interest.
To study the effect of TGFb signal inhibition on DCs and its eventual effect on atherosclerosis development, Lievens et Figure 1) . Secondly, plaques in mice with defective TGFb signalling (either systemically 9,10 or in T cells only 8, 11, 12 ) resulted in increased cellularity, T-cell infiltration, and a more unstable plaque phenotype (less collagen, less a-smooth muscle actin, and in some studies increased foam cells and MMP). Lievens et al. report increased pro-inflammatory cytokine production in supernatants of DCs from Apoe -/ -CD11cDNR after LPS stimulation or when co-cultured with wild-type CD4 + T cells, a finding that supports data from two other studies that found higher levels of IFNg and IL-4 production from T cells of mice whose TGFbRII signalling was inhibited. 8,11 Figure 1 summarizes the major aspects of each experimental model and the observed plaque phenotype. Conversely, a study published in 2009 used tetracycline-regulated cardiac-specific expression of constitutively active TGFb1, and found reduction in the size and number of atherosclerotic plaques in the aorta, increased collagen content, decreased aortic plaque T cell/macrophage numbers, and 40 -50% less mRNA for IFNg, TNFa, macrophage inflammatory protein-1a (MIP-1a, a), MIP-1b, MMP-9, and MMP-13. 14 Taken together, these studies constitute a solid body of evidence supporting a protective role for TGFb in atherosclerotic plaque development. Prior to this publication, the data suggested that TGFb plays a role in plaque formation and stabilization through generalized pro-fibrotic effects of TGFb, and/or through its direct inhibitory action on T cells [possibly via induction of regulatory T cells, which suppress lineage commitment of naïve T cells towards the T helper 1 (T H 1) phenotype]. The work of Lievens and colleagues suggests that an additional function of TGFb lies in its ability to affect DCs within atherosclerotic plaque, where DCs that are able to bind and signal through the TGFb pathway can interact with T cells, thereby inhibiting their commitment toward a pro-inflammatory lineage, thus decreasing pro-inflammatory cytokine production and probably also preventing their overpopulation of the plaque itself.
A recent paper by the late Ralph Steinman et al. described the presence of FLT3/FLT3-L-dependent dendritic cells which appear to inhibit atherosclerosis, at least in part, by supporting the Editorial differentiation and accumulation of T-regulatory (Treg) cells. 15 Steinman did not comment specifically on these cells' ability to respond to TGFb. It seems plausible that they would be able to. The new Lievens publication would lend credence to the idea that these FLT3/FLT3-L-dependent DCs may be the link between the effects of TGFb signalling and downstream inhibitory effects on effector T cells. Clearly, TGFb's anti-atherosclerotic role has many facets. At least some of the DCs expressing TGFbR are expected to be tolerogenic, but others promote pro-inflammatory T-cell responses including T H 1 and T H 17. 16 With current experimental techniques, it is difficult or impossible to distinguish between tolerogenic and pro-inflammatory DCs. Although the study of Lievens et al. does not relieve this uncertainty, it clearly shows that expressing a dominant negative TGFbR under the CD11c promoter has pro-inflammatory and pro-atherosclerotic consequences.
